Innovative Therapeutics OnCore BioPharma Inc., now operating under Arbutus Biopharma, specializes in developing novel therapeutics for chronic hepatitis B virus infection, showcasing strong potential for partnerships with healthcare providers and institutions focused on infectious diseases.

Latest Scientific Engagements The company's active participation in major conferences like AASLD and EASL, coupled with their presentations of new data, signals ongoing research advancements, creating opportunities to engage with researchers and clinicians interested in cutting-edge hepatitis B treatments.

Leadership & Growth Recent appointment of a new CEO and the launch of a Scientific Advisory Board comprising global leaders highlight strategic growth and focus, offering prospects for collaboration with industry experts and investors aligned with biotech innovation.

Funding & Revenue With minimal revenue but ongoing research activities, there is significant potential for sales development in securing partnerships or investment opportunities to support the company's clinical-stage product pipeline.

Technology Use & Presence Employing advanced tech stacks like OpenGraph, Akamai Bot Manager, and multi-site Drupal indicates a robust digital presence, providing a channel for targeted outreach and engagement to biotech and healthcare stakeholders.